vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $8.6M, roughly 1.1× Sunshine Biopharma Inc.). Sunshine Biopharma Inc. runs the higher net margin — -25.0% vs -234.3%, a 209.3% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -10.6%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 6.6%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
FHTX vs SBFM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $8.6M |
| Net Profit | $-21.7M | $-2.1M |
| Gross Margin | — | 35.3% |
| Operating Margin | -258.2% | -20.9% |
| Net Margin | -234.3% | -25.0% |
| Revenue YoY | 223.8% | -10.6% |
| Net Profit YoY | -11.1% | 0.8% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $8.6M | ||
| Q3 25 | $8.2M | $9.4M | ||
| Q2 25 | $7.6M | $9.4M | ||
| Q1 25 | $6.0M | $8.9M | ||
| Q4 24 | $2.9M | $9.6M | ||
| Q3 24 | $7.8M | $8.4M | ||
| Q2 24 | $6.9M | $9.3M | ||
| Q1 24 | $5.0M | $7.5M |
| Q4 25 | $-21.7M | $-2.1M | ||
| Q3 25 | $-15.8M | $-883.8K | ||
| Q2 25 | $-17.9M | $-1.8M | ||
| Q1 25 | $-18.8M | $-1.2M | ||
| Q4 24 | $-19.5M | $-2.2M | ||
| Q3 24 | $-19.1M | $-1.2M | ||
| Q2 24 | $-23.0M | $-494.3K | ||
| Q1 24 | $-25.0M | $-1.3M |
| Q4 25 | — | 35.3% | ||
| Q3 25 | — | 32.6% | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 32.2% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 25.3% | ||
| Q1 24 | — | 31.2% |
| Q4 25 | -258.2% | -20.9% | ||
| Q3 25 | -226.9% | -11.5% | ||
| Q2 25 | -279.2% | -21.8% | ||
| Q1 25 | -385.0% | -14.6% | ||
| Q4 24 | -840.5% | -21.7% | ||
| Q3 24 | -305.5% | -13.1% | ||
| Q2 24 | -386.6% | -13.6% | ||
| Q1 24 | -558.3% | -17.9% |
| Q4 25 | -234.3% | -25.0% | ||
| Q3 25 | -194.4% | -9.4% | ||
| Q2 25 | -237.3% | -18.8% | ||
| Q1 25 | -316.4% | -13.3% | ||
| Q4 24 | -682.9% | -22.5% | ||
| Q3 24 | -244.9% | -14.2% | ||
| Q2 24 | -333.6% | -5.3% | ||
| Q1 24 | -495.4% | -17.0% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.25 | $-0.54 | ||
| Q2 25 | $-0.28 | $-0.82 | ||
| Q1 25 | $-0.30 | $-0.44 | ||
| Q4 24 | $-0.23 | $49.77 | ||
| Q3 24 | $-0.31 | $-11.61 | ||
| Q2 24 | $-0.45 | $-43.48 | ||
| Q1 24 | $-0.59 | $-2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $23.0M |
| Total Assets | $198.1M | $30.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | — | ||
| Q3 25 | $89.3M | — | ||
| Q2 25 | $72.6M | — | ||
| Q1 25 | $61.0M | — | ||
| Q4 24 | $55.5M | — | ||
| Q3 24 | $57.7M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $79.3M | — |
| Q4 25 | $-108.5M | $23.0M | ||
| Q3 25 | $-89.7M | $24.2M | ||
| Q2 25 | $-76.7M | $25.7M | ||
| Q1 25 | $-61.7M | $22.7M | ||
| Q4 24 | $-45.5M | $23.5M | ||
| Q3 24 | $-28.3M | $25.0M | ||
| Q2 24 | $-14.3M | $23.5M | ||
| Q1 24 | $-97.5M | $24.8M |
| Q4 25 | $198.1M | $30.1M | ||
| Q3 25 | $205.0M | $31.5M | ||
| Q2 25 | $226.2M | $32.0M | ||
| Q1 25 | $258.7M | $29.2M | ||
| Q4 24 | $284.0M | $30.6M | ||
| Q3 24 | $308.4M | $30.1M | ||
| Q2 24 | $328.6M | $29.3M | ||
| Q1 24 | $255.0M | $31.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $-1.6M |
| Free Cash FlowOCF − Capex | — | $-1.6M |
| FCF MarginFCF / Revenue | — | -18.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $-1.6M | ||
| Q3 25 | $-18.9M | $-727.8K | ||
| Q2 25 | $-21.0M | $-1.3M | ||
| Q1 25 | $-24.0M | $-1.7M | ||
| Q4 24 | $-24.5M | $-3.4M | ||
| Q3 24 | $-21.0M | $-1.4M | ||
| Q2 24 | $-25.5M | $-4.6M | ||
| Q1 24 | $-29.3M | $-3.2M |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $-735.8K | ||
| Q2 25 | $-21.0M | $-1.4M | ||
| Q1 25 | $-24.0M | $-1.7M | ||
| Q4 24 | $-25.0M | $-3.5M | ||
| Q3 24 | $-21.3M | $-1.9M | ||
| Q2 24 | $-25.6M | $-5.6M | ||
| Q1 24 | $-29.4M | $-3.2M |
| Q4 25 | — | -18.9% | ||
| Q3 25 | — | -7.8% | ||
| Q2 25 | -278.2% | -15.2% | ||
| Q1 25 | -403.2% | -19.3% | ||
| Q4 24 | -875.3% | -36.6% | ||
| Q3 24 | -273.0% | -22.2% | ||
| Q2 24 | -371.0% | -59.7% | ||
| Q1 24 | -583.1% | -43.1% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.3% | 1.7% | ||
| Q1 25 | 0.5% | 0.1% | ||
| Q4 24 | 16.8% | 1.1% | ||
| Q3 24 | 4.0% | 6.1% | ||
| Q2 24 | 0.2% | 10.5% | ||
| Q1 24 | 2.0% | 0.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
